Pharmacotherapy for post-traumatic stress disorder

Expert Review of Clinical Pharmacology

Volumn 2, Issue 1, 2009, Pages 77-86

  Alderman, Christopher P ^a,b   McCarthy, Linda C ^a   Marwood, Anita C ^a  

^a REPATRIATION GENERAL HOSPITAL   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Adrenergic modulator; Anticonvulsant; Benzodiazepine; Pharmacotherapy; Post traumatic stress disorder; Selective serotonin reuptake inhibitor

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; IMIPRAMINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PHENELZINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIAGABINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ABNORMAL BEHAVIOR; AGITATION; CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILY THERAPY; GROUP THERAPY; HUMAN; MARITAL THERAPY; POSTTRAUMATIC STRESS DISORDER; REVIEW; SEDATION; SIDE EFFECT; WEIGHT GAIN;

EID: 67649328596     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.2.1.77     Document Type: Review

References (128)

1. Diagnostic and Statistical Manual of Mental Disorders (4th Edition) (DSM-IV). American Psychiatric Association, DC, USA 424-429 (1994).
2. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB, Posttraumatic stress disorder in the National Comorbidity Survey. Arch. Gen. Psychiatry 52, 1048-1060 (1995).
3. Yehuda R. Post-traumatic stress disorder. N. Engl. J. Med. 346, 106-114 (2002).
4. Foa EB, Davidson JR, Frances A. Treatment of posttraumaric stress disorder. J. Clin. Psychiatry 60(Suppl. 16), 6-74 (1999).
5. van der Kolk BA. The psychobiology of posttraumatic stress disorder. J. Clin. Psychiatry 58, 16-24 (1997).
6. Pitman RK, Gilbertson MW, Gurvits TV et al. Clarifying the origin of biological abnormalities in PTSD through the study of identical twins discordant for combat exposure. Ann. NY Acad. Sci. 1071, 242-254 (2006).
7. Australian Centre for Posttraumatic Mental Health. Australian Guidelines for the Treatment of Adults with Acute Stress Disorder and Posttraumatic Stress Disorder. ACPMH, Melbourne, Australia (2007).
8. Post-traumatic stress disorder (PTSD). The Management of PTSD in Adults and Children in Primary and Secondary Care. National Institute for Clinical Excellence, London, UK (2005).
9. Practice Guideline for the Treatment of Patients with Acute Stress Disorder and Posttraumatic Stress Disorder. American Psychiatric Association, DC, USA (2004).
10. Baldwin DS, Polkinghorn C. Evidence-based pharmacotherapy of generalized anxiety disorder. Int. J. Neuropsychopharmacol. 8, 293-302 (2005).
11. Cahill SP, Foa EB, Rothbaum BO et al. Augmentation of sertraline with prolonged exposure (PE) in the treatment of PTSD: does PE protect against relapse? Presented at: The Annual Convention of the Anxiety Disorders Association of America. Toronto, ON, Canada 27-30 March, 2003 (Poster).
12. Boscarino JA. Diseases among men 20 years after exposure to severe stress: implications for clinical research and medical care. Psychosom. Med. 59, 605-614 (1997).
13. Solomon SD, Davidson JRT. Trauma: prevalence, impairment, service use, and cost. J. Clin. Psychiatry 58 (Suppl. 9), 5-11 (1997).
14. Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their structure and function. DICP 24, 1093-1097 (1990).
15. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am. J. Psychiatry 153, 311-320 (1996).
16. Hogben GL, Cornfield RB. Treatment of traumatic war neurosis with phenelzine. Arch. Gen. Psychiatry 38, 440-445 (1981).
17. Levenson H, Lanman R, Rankin M. Traumatic ward neurosis and phenelzine. Arch. Gen. Psychiatry 39, 1345 (1982).
18. Davidson J, Walker JI, Kilts C. A pilot study of phenelzine in the treatment of post-traumatic stress disorder. Br. J. Psychiatry 150, 252-255 (1987).
19. Lere B, Bleich A, Kotler M, Garb R, Hertzberg M, Levin B. Posttraumatic stress disorder in Israeli combat veterans. Effect of phenelzine treatment. Arch. Gen. Psychiatry 44, 976-981 (1987).
20. Kosten TR, Frank JB, Dan E, McDougle CJ, Giller EL. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J. Nerv. Ment. Dis. 179, 366-370 (1991).
21. Falcon S, Ryan C, Chamberlain K, Curtis G. Tricyclics: possible treatment for posttraumatic stress disorder. J. Clin. Psychiatry 46, 385-388 (1985).
22. Reist C, Kauffmann CD, Haier RJ, Sangdahl C, DeMet EM, Chicz-DeMet A et al. A controlled trial of desipramine in 18 men with posttraumatic stress disorder. Am. J. Psychiatry 146, 513-516 (1989).
23. Davidson J, Kudler H, Smith R et al. Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch. Gen. Psychiatry 47, 259-266 (1990).
24. Davidson JR, Kudler HS, Saunders WB et al. Predicting response to amitriptyline in posttraumatic stress disorder. Am. J. Psychiatry 150, 1024-1029 (1993).
25. Blake DJ. Treatment of posttraumatic stress disorder with tricyclic antidepressants. South Med. J. 79, 201-204 (1986).
26. den Boer M, Op der Belde W, Falger RJ, Hoveas JE, deFroen JH, van Duijn H. Fluvoxamine treatment for chronic PTSD. Psychother. Psychosomat. 57, 158-163 (1991).
27. McDougle CJ, Southwick SM, Charney DS, James St RL. An open trial of fluoxetine in the treatment of posttraumatic stress disorder. J. Clin. Psychopharmacol. 11, 325-327 (1991).
28. Shay J. Fluoxetine reduces explosiveness and elevates mood of Vietnam combat veterans with PTSD. J. Trauma Stress 5, 97-101 (1992).
29. Nagy LM, Morgan CA, Southwick SM, Charney DS. Open prospective trial of fluoxetine for posttraumatic stress disorder. J. Clin. Psychopharmacol. 13, 107-113 (1993).
30. March JS. Fluoxetine and fluvoxamine in PTSD. Am. J. Psychiatry 149, 413 (1992).
31. van der Kolk BA, Dreyfuss D, Michaels M et al. Fluoxetine in posttraumatic stress disorder. J. Clin. Psychiatry 55, 517-522 (1994).
32. Kline NA, Dow BM, Brown SA, Matloff JL. Sertraline efficacy in depressed combat veterans with posttraumatic stress disorder. Am. J. Psychiatry 151, 621 (1994).
33. Fichtner CG, Arora RC, O'Connor FL, Crayton JW. Platelet paroxetine binding and fluoxetine pharmacotherapy in posttraumatic stress disorder: preliminary observations on a possible predictor of clinical treatment response. Life Sciences 54, PL39-PL44 (1994).
34. Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database of Syst. Rev. (1), CD002795 (2006).
35. Davidson JR. Pharmacological treatment of acute and chronic stress following trauma. J. Clin. Psychiatry 67(Suppl. 2), 34-39 (2006).
36. Rothbaum BO, Ninan PT, Thomas L. Sertraline in the treatment of rape victims with posttraumatic stress disorder. J. Trauma Stress 9, 865-871 (1996).
37. Brady K, Pearlstein T, Asnis GM et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 283, 1837-1844 (2000).
38. Davidson JR, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM. Multicentre, double blind comparison of sertraline and placebo in the treatment of post-traumatic stress disorder. Arch. Gen. Psychiatry 58, 485-492 (2001).
39. Brady K, Sonne S, Anton RF, Randall CI, Back SE, Simpson K. Sertraline in the treatment of co-occurring alcohol dependence and posttraumaric stress disorder. Alcohol Clin. Exp. Res. 29, 395-401 (2005).
40. Zohar J, Amital D, Miodownik C et al. Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J. Clin. Psychopharmacol. 22, 190-195 (2002).
41. Stein DJ, van der Kolk BA, Austin C, Fayyad R, Clary C. Efficacy of sertraline in posttraumatic stress disorder secondary to interpersonal trauma or childhood abuse. Ann. Clin. Psychiatry 18, 243-249 (2006).
42. Connor KM, Sutherland SM, Tupler LA, Malik ML, Davidson JR. Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study. Br. J. Psychiatry 175, 17-22 (1999).
43. Martenyi F, Brown EB, Zhang H, Koke SC, Prakash A. Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder. Br. J. Psychiatry 181, 315-320 (2002).
44. Martenyi F, Soldatenkova V. Fluoxetine in the acute treatment and relapse prevention of combat-related post-traumatic stress disorder: analysis of the veteran group of a placebo-controlled, randomized clinical trial. Eur. Neuropsychopharmacol. 16, 340-349 (2006).
45. Marmar CR, Schoenfeld F, Weiss DS et al. Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder. J. Clin. Psychiatry 57(Suppl. 8) 66-70 (1996).
46. Marshall RD, Schneier FR, Fallon BA et al. An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder. J. Clin. Psychopharmacol. 18, 10-18 (1998).
47. Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, Pitts CD. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J. Clin. Psychiatry 62, 860-868 (2001).
48. Marshall RD, Beebe KL, Oldham M, Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am. J. Psychiatry 158, 1982-1988 (2001).
49. Marshall RD, Lewis-Fernandez R, Blanco C et al. A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depress. Anxiety 24, 77-84 (2007).
50. Seedat S, Stein DJ, Emsley RA. Open trial of citalopram in adults with post-traumatic stress disorder. Int. J. Neuropsychpharmacol. 3, 135-140 (2000).
51. Robert S, Hamner MB, Ulmer HG, Lorberbaum JP, Durkalski VL, Open-label trial of escitalopram in the treatment of posttraumatic stress disorder. J. Clin. Psychiatry 2067, 1522-1526 (2006).
52. Tucker P, Ruwe WD, Masters B et al. Neuroimmune and cortisol changes in selective serotonin reuptake inhibitor and placebo treatment of chronic posttraumatic stress disorder. Biol. Psychiatry 56, 121-128 (2004).
53. Hertzberg MA, Feldman ME, Beckham JC, Kudler HS, Davidson JR. Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Ann. Clin. Psychiatry 12, 101-105 (2000).
54. Martenyi F, Brown EB, Caldwell CD. Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study. J. Clin. Psychopharmacol. 27, 166-170 (2007).
55. Davidson J, Baldwin D, Stein DJ et al. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch. Gen. Psychiatry 65, 1158-1165 (2006).
56. Davidson J, Rothbaum BO, Tucker P, Asnis G, Benattia I, Musgnung JJ. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J. Clin. Psychopharmacol. 26, 259-267 (2006).
57. Neal LA, Shapland W, Fox C. An open trial of moclobemide in the treatment of post-traumatic stress disorder. Into Clin. Psychopharmacol. 12, 231-237 (1997).
58. Onder E, Tural U, Aker T. A comparative study of fluoxetine, moclobemide, and tianeptine in the treatment of posttraumatic stress disorder following an earthquake. Eur. Psychiatry 21, 174-179 (2006).
59. Becker ME, Hertzberg MA, Moore SD, Dennis MF, Bukenya DS, Beckham JC. A placebo-controlled trial of bupropion SR in the treatment or chronic posttraumatic stress disorder. J. Clin. Psychopharmacol. 27, 193-197 (2007).
60. Spivak B, Straus RD, Shaked G, Shabash E, Kotler M, Weizman A. Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial. J. Clin. Psychopharmacol. 26, 152-156 (2006).
61. Connor, KM, Davidson JRT, Weisler RH, Ahearn E. A pilot study of mirtszapine in post-traumatic stress disorder. Int. Clin. Psychopharmacol. 14, 29-31 (1999).
62. Bahk W-M, Pae C-U, Tsoh J et al. A Effects of mirtazapine in patients with post-traumatic stress disorder in Korea: a pilot study. Hum. Psychopharmacol. 17, 341-344 (2002).
63. Kim W, Pae C-U, Chae J-H, Jun T-Y, Bahk W-M. The effectiveness of mirtazapine in the treatment of post-traumatic stress disorder: a 24 week continuation therapy. Psychiatry Clin. Neurosci. 59, 743-747 (2005).
64. Davidson JR, Weisler RH, Butterfield MI et al. Mirtazapine vs placebo in posttraumatic stress disorder: a pilot trial. Biol. Psychiatry 53, 188-191 (2003).
65. Lewis JD. Mirtazapine for PTSD nightmares. Am. J. Psychiatry 159, 1948-1949 (2002).
66. Chung MY, Min KH, Kim SS, Kim WC, Jun EM. Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Hum. Psychopharmacol. 19, 489-494 (2004).
67. Brunello N, Davidson JRT, Deahl M et al. Posttraumatic stress disorder: diagnosis and epidemiology, comorbidity and social consequences, biology and treatment. Neuropsychobiology 43, 150-162 (2001).
68. Londborg PD, Hegel MT, Goldstein S et al. Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. J. Clin. Psychiatry 62, 325-331 (2001).
69. Ciccone PE, Amzarek A, Weisbrot M, Greenstein RA, Olsem K, Zimmerman J. Pharmacotherapy for PTSD. Am. J. Psychiatry 145, 1484-1485 (1988).
70. Dieperink M, Erbes C, Leskela J et al. Comparison of treatment for post-traumatic stress disorder amongst three department of Veterans Affairs medical centers. Milit. Med. 170, 305-308 (2005).
71. Hamner MB, Robert S. Emerging roles for the atypical antipsychotics in chronic post-traumatic stress disorder. Expert Rev. Neurotherapeutics 5, 267-275 (2005).
72. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JRT. Evidence-based guidelines for the pharmacological management of anxiety disorders: recommendations from the British Association for Psychopharmacology. J. Psychpharmacol. 19, 567-596 (2005).
73. Ursano RJ, Bell C, Eth S et al. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Am. J. Psychiatry 161(11 Suppl.), 3-31 (2004).
74. Foa EB, Davidson JRT, Frances A. The Expert Consensus Guideline Series: Treatment of Posttraumatic Stress Disorder. J. Clin. Psychiatry 60(Suppl. 16), 3-76 (1999).
75. Seedat S, Stein MB, Oosthuizen PP, Emsley RA, Stein DJ. Linking posttraumatic stress disorder and psychosis: a look at epidemiology, phenomenology and treatment. J. Nerv. Ment. Dis. 191, 675-681 (2003).
76. Ahearn EP, Krohn A, Connor KM, Davidosn JRT. Pharmacologic treatment of posttraumatic stress disorder: a focus on antipsychotic use. Ann. Clin. Pyschiatry 15, 193-201 (2003).
77. Kozari-Kovaci D, Pivac N, Muck-Seler D, Rothbaum BO. Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. J. Clin. Psychiatry 66, 922-927 (2005).
78. Bartzokis G, Lu PH, Turner J, Mintz J, Saunders CS. Adjunctive risperidone in the treatment of combat-related posttraumatic stress disorder. Biol. Psychiatry 57, 474-479 (2005).
79. Reich DB, Winternitz S, Hennen J, Watts T, Stanculescu C. A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. J. Clin. Psychiatry 65, 1601-1606 (2004).
80. Monelly EP, Ciraulo DA, Knapp C, Keane T. Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J. Clin. Psychopharmacol. 23, 193-196 (2003).
81. Petty F, Brannan S, Casada J et al. Olanzapine treatment for post-traumatic stress disorder: an open-label study. Int. Clin. Psychopharmacol. 16, 331-337 (2001).
82. Pivac N, Kozaric-Kovacic D, Muck-Seler D. Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorder. Psychopharmacology 175, 451-456 (2004).
83. Hamner-MB, Dietsch SE, Brodrick PS, Ulmer HG, Lorberbaum JP. Quetiapine treatment in patients with posttraumatic stress disorder: an open trail of adjunctive therapy. J. Clin. Psychopharmacol. 23, 15-20 (2003).
84. Kozaric-Kovacic D, Pivac N. Quetiapine treatment in an open trial in combat-related post-traumatic stress disorder with psychotic features. Int. J. Neuropsychopharmacol. 10, 253-261 (2007).
85. Lipper S, Davidson JR, Grady TA, Edinger JD, Hammett EB, Mahorney SL. Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics 27, 849-854 (1986).
86. Wolf ME, Alavi A, Mosnaim AD. Posttraumatic stress disorder in Vietnam veterans clinical and EEG findings: possible therapeutic effects of carbamazepine. Biol. Psychiatry 23, 642-646 (1988).
87. Fesler FA. Valproate in combat-related posttraumatic stress disorder. J. Clin. Psychiatry 52, 361-364 (1991).
88. Clark RD, Canive JM, Calais LA, Qualls C, Tuason VB. Divalproex in post-traumatic stress disorder: an open-label clinical trial. J. Trauma Stress 12, 395-401 (1999).
89. Hertzberg MA, Butterfield MI, Feldman ME et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol. Psychiatry 45, 1226-1229 (1999).
90. Hamner MB, Brodrick PS, Labbate LA. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann. Clin. Psychiatry 13, 141-146 (2001).
91. Taylor FB. Tiagabine for posttraumatic stress disorder: a case series of 7 women. J. Clin. Psychiatry 64, 1421-1425 (2003).
92. Connor KM, Davidson JR, Weisler RH, Zhang W, Abraham K. Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology 184, 21-25 (2006).
93. Davidson JR, Brady K, Mellman TA, Stein MB, Pollack MH. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J. Clin. Psychopharmacol. 27, 85-88 (2007).
94. Berlant J, van Kammen DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J. Clin. Psychiatry 63(1), 15-20 (2002).
95. Berlant JL. Topiramate in posttraumatic stress disorder: preliminary clinical observations. J. Clin. Psychiatry 62(Suppl. 17), 60-63 (2001).
96. Berlant JL. Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry 18(4), 24 (2004).
97. Tucker P, Trautman RP, Wyatt DB et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 68(2), 201-206 (2007).
98. Akuchekian S, Amanat S. The Comparison of topiramate and placebo in the treatment of posttraumatic stress disorder: a randomized, double-blind study. J. Res. Med. Sci. 9(5), 240-244 (2004).
99. Johnson BA, Rosenthal N, Capece JA et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298(14), 1641-1651 (2007).
100. Braun P, Greenberg D, Dasberg H, Lerer B. Core symptoms of post-traumatic stress disorder unimproved by alprazolam treatment. J. Clin. Psychiatry 51, 236-238 (1990).
101. Cates ME, Bishop MH, Davis LL, Lowe JS, Wooley TW. Clonazepam for treatment of sleep disturbances associated with combat-related posttraumatic stress disorder. Ann. Pharmacother. 38, 1395-1399 (2004).
102. Gelpin E, Bonne O, Peri T, Brandes D, Shalev AY. Treatment of recent trauma survivors with benzodiazepines: a prospective study. J. Clin. Psychiatry 57, 390-394 (1996).
103. Jacobsen LK, Southwick SM, Kosten TR. Substance use disorders in patients with post-traumatic stress disorder: a review of the literature. Am. J. Psychiatry 158, 1184-1190 (2001).
104. Kosten TR, Fontana A, Sernyak MJ, Rosenheck R. Benzodiazepine use in posttraumatic stress disorder among veterans with substance abuse. J. Nerv. Ment. Dis. 188, 454-459 (2000).
105. Ballenger JC, Davidson JR, Lecrubier Y et al. Consensus statement update on posttraumatic stress disorder from the international consensus group on depression and anxiety. J. Clin. Psychiatry 65(Suppl. 1), 55-62 (2004).
106. Alderman CP, Gilbert AL, Condon JT. Characteristics of tranquilizer use among Australian Vietnam war veterans. Ann. Pharmacother. 34, 1243-1248 (2000).
107. Hajak G, Muller WE, Wittchen HU, Pittrow D, Kirch W. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiologicai data. Addiction 98, 1371-1378 (2003).
108. Bianchi M, Musch B. Zopiclone discontinuation: review of 25 studies assessing withdrawal and rebound phenomena. Int. Clin. Psychopharmacol. 5, 139-145 (1990).
109. Southwick SM, Bremmer JD, Rasmusson A, Morgan CA, Amsten A, Charney DS. Role of norepinephrine in the pathophysiology and treatment of post-traumatic stress disorder. Biol. Psychiatry 46, 1192-1204 (1999).
110. Coupland NJ. Brain mechanisms and neurotransmitters. In: Post-Traumatic Stress Disorder - Diagnosis, Management and Treatment. Nutt DM, Davidson JR, Zohar J (Eds). Martin Duniz, London, UK, 69-100 (2000).
111. 1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with post-traumatic stress disorder: a report of four cases. J. Clin. Psychiatry 61, 129-133 (2000).
112. Raskind MA, Peskind ER, Kanter ED et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am. J. Psychiatry 160, 371-373 (2003).
113. Brkanac Z, Pastor JF, Storck M. Prazosin in PTSD. J. Am. Acad. Child Adolesc. Psychiatry 42, 384-385 (2003).
114. Boehnlein JK, Kinzie JD. Pharmacological reduction of CNS noradrenergic activity in PTSD: the case for clonidine and prazosin. J. Psychiatr. Pract. 13, 72-78 (2007).
115. Peskind ER, Bonner LT, Hoff DJ, Raskind MA. Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder. J. Geriatr. Psychiatry Neurol. 16, 165-171 (2003).
116. Raskind MA, Thompson C, Petrie EC et al. Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder. J. Clin. Psychiatry 63, 565-568 (2002).
117. Taylor F, Raskind MA. The α1-adrenergic antagonist prazosin improves sleep and nightmares in civilian trauma posttraumatic stress disorder. J. Clin. Psychopharmacol. 22, 82-85 (2002).
118. Kinzie JD, Leung P. Clonidine in Cambodian patients with posttraumatic stress disorder. J. Nerv. Ment. Dis. 177, 546-550 (1989).
119. Taylor F, Cahill L. Propranolol for reemergent posttraumatic stress disorder following an event of retraumatization: a case study. J. Trauma Stress 15, 433-437 (2002).
120. Swartz CM. Betaxolol in anxiety disorders. Ann. Clin. Psychiatry 10, 9-14 (1998).
121. Pitman RK, Sanders KM, Zusman RM et al. Pilot study of sencondary prevention of posttraumatic stress disorder with propranolol. Biol. Psychiatry 51, 189-192 (2002).
122. Vaiva G, Ducrocq F, Jezequel K et al. Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol. Psychiatry 54, 947-949 (2003).
123. Stein MB, Kerridge C, Dimsdale JE, Hoyt DB. Pharmacotherapy to prevent PTSD: results from a randomized controlled proof-of-concept trial in physically injured patients. J. Trauma Stress 20, 923-932 (2007).
124. Friedman MJ. Future pharmacotherapy for post-traumatic stress disorder: prevention and treatment. Psychiatr. Clin. North Am. 25, 427-441 (2002).
125. Schelling G, Stoll C, Kapfhammer HP et al. The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder and health-related quality of life in survivors. Crit. Care Med. 27, 2678-2683 (1999).
126. Schelling G, Briegel J, Roozendaal B, Stoll C, Rothenhäusler HB, Kapfhammer HP. The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder in survivors. Biol. Psychiatry 50, 978-985 (2001).
127. Schelling G, Kilger E, Roozendaal B et al. Stress doses of hydrocortisone, traumatic memories, and symptoms of posttraumatic stress disorder in patients after cardiac surgery: a randomized study. Biol. Psychiatry 55, 627-633 (2004).
128. Aerni A, Traber R, Hock C et al. Low-dose cortisol for symptoms of posttraumatic stress disorder. Am. J. Psychiatry 161, 1488-1490 (2004).